
Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary ...
Opthea announced results from COAST, its phase 3 clinical trial in patients with wet age-related macular degeneration (wet AMD). COAST (Combination OPT-302 with Aflibercept Study) evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with …